The microbiome is seemingly connected to every aspect of our health nowadays and now one of the world’s biggest cancer charities, Cancer Research UK has dedicated up to $ 25 million to finding out whether it might be involved in colorectal cancer, the third most common cancer in the U.S.
There are many lifestyle factors that influence people’s risk of developing colorectal cancer. Researchers are discovering that the impact of some of these factors on the microbiome, such as diet and obesity may play an important role in colorectal cancer development, progression and even response to cancer drugs.
The ambitious project involves 14 investigators spread between six different countries, but is led jointly by two U.S. researchers; Professor Matthew Meyerson of Dana-Faber Cancer Institute and Harvard Medical School and Professor Wendy Garrett from the Harvard T.H. Chan School of Public Health. Meyerson specializes in cancer genetics and Garrett’s expertise is immunology and infectious diseases.
“The colon is the most densely populated microbial environment on the planet. Our tumors and cancers also harbor microbes that can contribute to whether we respond to a drug or not. There are wide opportunities for thinking about cancer, risk, development, treatment and cancer care through the lens of the microbiome,” said Garrett.
One bacterial species called Helicobacter pylori has long been accepted to cause stomach cancer, but its link to colorectal cancer is uncertain, although there is growing evidence to suggest it is involved in some cases. There is also much interest in bacteria found in normal gut microbiome that are not currently thought to have any role in disease.
“We and others have shown that bacteria can promote colon cancer in a number of model systems and if you treat these infections it appears to be possible to limit the growth of these colon cancers. We don’t really currently understand this in detail and whether there is enough evidence for this happening in people.” said Meyerson.
The team will use a variety of experimental systems to investigate the possible relationship between bacteria and colorectal cancer including animal models and also organoids; tiny organs in a dish made from patients with colon cancer. The team will also look at the effect of current treatments for colorectal cancer on the microbiome by collecting samples from patients receiving treatment.
“With new genomic technologies, we can map the microbiome in incredible detail, so now is the right time to be investigating this phenomenon of cancer. With this information, we hope to develop new microbiome-targeted therapies for colorectal cancer,” said Meyerson.
This work is only just beginning and time will tell whether the team get to a point where they have enough evidence that the microbiome is involved in colorectal cancer to consider trying to change it to treat or even prevent the disease, but they are well set-up to do this work if early data is persuasive.
“First of all we have to consider safety with any kind intervention. We have several clinical trialists involved in the study and a whole clinical trial network supporting this network and poised to jump in,” said Garrett.
Cancer Research UK, which has historically funded researchers based in UK hospitals and universities is now branching out to fund ‘Grand Challenges’, which link together traditionally separated research fields to come up with innovative solutions to some of the biggest challenges in cancer research.
“Cancer Research UK’s Grand Challenge is set up differently from almost all other research funding, in that it aims to bring together the brightest minds from a range of disciplines and from around the world to focus on specific challenges in cancer research. We received 134 applications from 41 different countries which were narrowed down to the final three projects for this year’s funding round,” said Iain Foulkes, PhD, Cancer Research UK’s executive director of research and innovation.
The other two projects focus on finding new ways to tackle cancers caused by chronic inflammation and develop a deeper understanding of why cancers grow in some tissues but not in others. Both are also led by U.S.-based researchers with the funding provided for all three projects totalling around $ 75 million.
“Cancer is a global problem that requires a global solution. The quality of the applications proved that the best science happens when the world’s top scientists work in collaboration with each other,” said Foulkes.